Entropy Technologies LP Makes New $214,000 Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Entropy Technologies LP purchased a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 12,300 shares of the company's stock, valued at approximately $214,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CWM LLC lifted its position in Travere Therapeutics by 158.5% in the third quarter. CWM LLC now owns 4,999 shares of the company's stock worth $70,000 after purchasing an additional 3,065 shares during the period. Creative Planning lifted its position in Travere Therapeutics by 4.3% in the third quarter. Creative Planning now owns 23,938 shares of the company's stock worth $335,000 after purchasing an additional 995 shares during the period. Semanteon Capital Management LP bought a new position in Travere Therapeutics in the third quarter worth $513,000. China Universal Asset Management Co. Ltd. lifted its position in Travere Therapeutics by 64.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 14,712 shares of the company's stock worth $206,000 after purchasing an additional 5,767 shares during the period. Finally, Rice Hall James & Associates LLC lifted its position in Travere Therapeutics by 24.4% in the third quarter. Rice Hall James & Associates LLC now owns 94,736 shares of the company's stock worth $1,325,000 after purchasing an additional 18,562 shares during the period.

Insider Buying and Selling

In other news, CAO Sandra Calvin sold 54,244 shares of Travere Therapeutics stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the transaction, the chief accounting officer now owns 54,410 shares in the company, valued at $1,360,250. The trade was a 49.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Peter Heerma sold 1,584 shares of Travere Therapeutics stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $18.94, for a total value of $30,000.96. Following the transaction, the insider now owns 106,374 shares in the company, valued at $2,014,723.56. This trade represents a 1.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 218,425 shares of company stock worth $4,674,259 over the last three months. 3.75% of the stock is currently owned by company insiders.

Travere Therapeutics Trading Up 0.5 %

TVTX stock traded up $0.13 during midday trading on Tuesday, reaching $23.04. The stock had a trading volume of 498,102 shares, compared to its average volume of 1,573,082. The business has a fifty day simple moving average of $19.30 and a two-hundred day simple moving average of $16.29. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The firm has a market cap of $1.80 billion, a price-to-earnings ratio of -5.06 and a beta of 0.72. Travere Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $25.29.

Analyst Upgrades and Downgrades

TVTX has been the subject of several recent analyst reports. Wells Fargo & Company upgraded Travere Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $9.00 to $27.00 in a research note on Monday, October 21st. Evercore ISI increased their price objective on Travere Therapeutics from $33.00 to $45.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. HC Wainwright increased their price objective on Travere Therapeutics from $18.00 to $22.00 and gave the stock a "buy" rating in a research note on Wednesday, January 15th. Canaccord Genuity Group increased their price objective on Travere Therapeutics from $22.00 to $45.00 and gave the stock a "buy" rating in a research note on Wednesday, February 12th. Finally, Barclays increased their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the stock an "overweight" rating in a research note on Friday, November 1st. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, Travere Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $27.77.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.